Oramed Pharmaceuticals Inc (ORMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) has a cash flow conversion efficiency ratio of -0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($238.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Oramed Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Oramed Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Oramed Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Oramed Pharmaceuticals Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Oramed Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oramed Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
THETA GOLD MNS LTD
F:3LM
|
N/A |
|
Hsing Ta Cement Co Ltd
TW:1109
|
0.042x |
|
Centrum Medyczne ENEL-MED SA
WAR:ENE
|
0.238x |
|
Capital Small Finance Bank Limited
NSE:CAPITALSFB
|
0.052x |
|
Premium Income Corporation
TO:PIC-A
|
-0.040x |
|
Ge Shen Corporation Bhd
KLSE:7197
|
-0.021x |
|
Fu Yu Property Co Ltd
TWO:4907
|
0.079x |
|
Torrid Holdings Inc
NYSE:CURV
|
0.028x |
Annual Cash Flow Conversion Efficiency for Oramed Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Oramed Pharmaceuticals Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Oramed Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $199.74 Million | $-9.14 Million | -0.046x | +20.89% |
| 2024-12-31 | $145.35 Million | $-8.41 Million | -0.058x | +8.43% |
| 2023-12-31 | $162.89 Million | $-10.29 Million | -0.063x | +66.71% |
| 2022-12-31 | $151.16 Million | $-28.70 Million | -0.190x | -4.45% |
| 2021-12-31 | $116.52 Million | $-21.18 Million | -0.182x | +51.95% |
| 2020-12-31 | $32.88 Million | $-12.44 Million | -0.378x | +43.30% |
| 2019-12-31 | $19.39 Million | $-12.94 Million | -0.667x | -41.64% |
| 2018-12-31 | $31.11 Million | $-14.66 Million | -0.471x | -55.43% |
| 2017-12-31 | $19.24 Million | $-5.83 Million | -0.303x | -270.53% |
| 2016-12-31 | $26.19 Million | $4.66 Million | 0.178x | +189.22% |
| 2015-12-31 | $24.83 Million | $-4.95 Million | -0.199x | -1.82% |
| 2014-12-31 | $20.79 Million | $-4.07 Million | -0.196x | +53.15% |
| 2013-12-31 | $8.13 Million | $-3.40 Million | -0.418x | +31.45% |
| 2012-12-31 | $3.78 Million | $-2.30 Million | -0.609x | -36.17% |
| 2011-12-31 | $3.72 Million | $-1.67 Million | -0.447x | +73.81% |
| 2010-12-31 | $830.27K | $-1.42 Million | -1.708x | -108.25% |
| 2009-12-31 | $2.75 Million | $-2.25 Million | -0.820x | -105.12% |
| 2008-12-31 | $4.59 Million | $-1.84 Million | -0.400x | +66.42% |
| 2007-12-31 | $513.00K | $-611.00K | -1.191x | -242.52% |
| 2006-12-31 | $-432.72K | $-361.61K | 0.836x | -7.39% |
| 2005-12-31 | $-44.81K | $-40.44K | 0.902x | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more